Legend Biotech Corp - Company Profile
Powered by 
All the data and insights you need on Legend Biotech Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Legend Biotech Corp Strategy Report
- Understand Legend Biotech Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Legend Biotech Corp (Legend Biotech), a subsidiary of Genscript Biotech Corp, develops, manufactures, and commercializes novel therapies to treat life-threatening diseases. The company develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer (NK) cell-based immunotherapy. Legend Biotech also operates research and development sites. The company operates in the Americas and Europe. Legend Biotech is headquartered in Piscataway, New Jersey, the US.
Headquarters
United States of America
Address
2101 Cottontail Lane, Somerset, New Jersey, 08873
Website
www.legendbiotech.com
Telephone
1 732 3175050
No of Employees
1,800
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LEGN (NASD)
Revenue (2022)
$285.1M
143.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-16.1%
(2022 vs 2021)
Market Cap*
$8.4B
Net Profit Margin (2022)
XYZ
52.4%
(2022 vs 2021)
* As of and is in US$
Legend Biotech Corp premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| GPC3 |
| GCC |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Stake Sale | In May, the company sold 0.09% stake to Hillhouse Investment Management. |
| 2023 | Contracts/Agreements | In March, the company agreed to sell 5,468,750 American Depositary Shares. |
| 2022 | Regulatory Approval | In June, the company received the US Food and Drug Administration clearance for its investigational new drug application to evaluate LB1908 in a Phase 1 clinical trial in the US. |
Competitor Comparison
| Key Parameters | Legend Biotech Corp | Novartis AG | Bristol-Myers Squibb Co | bluebird bio Inc | Marker Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | United States of America |
| City | Somerset | Basel | Princeton | Somerville | Houston |
| State/Province | New Jersey | - | New Jersey | Massachusetts | Texas |
| No. of Employees | 1,800 | 76,057 | 34,100 | 323 | 8 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Fangliang Zhang | Chairman | Executive Board | 2022 | 58 |
| Ying Huang | Chief Executive Officer; Director | Executive Board | 2021 | 50 |
| Lori Macomber | Chief Financial Officer | Senior Management | 2022 | 52 |
| Mythili Koneru | Chief Medical Officer | Senior Management | 2023 | - |
| Guowei Fang | Chief Scientific Officer; Head - Business Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer